FORTIS: Future Performance Will Balance Recent Acquisition And Legal Developments

Analysts have increased their price target for Fortis Healthcare from ₹983.07 to ₹1,023.56. They cite improved profit margin forecasts despite slightly lower revenue growth expectations.

What's in the News

• Northern Tk Venture Pte Ltd has completed the acquisition of a 26.1% stake in Fortis Healthcare Limited for INR 33.5 billion, following regulatory approvals and the conclusion of the tendering period (Key Developments).
• The Supreme Court of India has been involved in ongoing legal proceedings, resulting in delays to the completion of the open offer. The Court has also issued subsequent directives for a forensic audit and contempt proceedings (Key Developments).
• A recent Board Meeting was scheduled for November 11, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).
• A Special Shareholders Meeting is scheduled for November 15, 2025, to consider appointing Dr. Keith Hsiu Chin Lim as a Non-Independent and Non-Executive Director (Key Developments).
• Fortis Healthcare has entered into a strategic collaboration with Ekana Group to manage an upcoming 550-bed super specialty hospital in Lucknow, with the goal of establishing it as a Centre of Excellence for tertiary care (Key Developments).

Valuation Changes

• The consensus analyst price target has risen slightly from ₹983.07 to ₹1,023.56.
• The discount rate increased marginally from 12.73% to 12.76%.
• The revenue growth expectation decreased modestly from 16.62% to 16.31%.
• The net profit margin forecast has improved from 15.54% to 15.97%.
• The future P/E ratio is projected to decline slightly from 53.29x to 52.62x.